RAPT Therapeutics (RAPT) has received a new Buy rating, initiated by LifeSci Capital analyst, Sam Slutsky.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Sam Slutsky’s rating is based on RAPT Therapeutics’ promising development in the field of immunology, particularly with their lead asset, RPT904. This long-acting anti-IgE monoclonal antibody is being developed for treating food allergies and chronic spontaneous urticaria, which are significant markets in the US. The potential of RPT904 to offer a longer-lasting treatment with reduced injection frequency compared to existing therapies like Xolair presents a substantial advantage.
Additionally, RAPT’s strategic partnerships and upcoming clinical trials further support the Buy rating. The anticipated Phase 2 readouts from their partner, Jemincare, in asthma and CSU, along with RAPT’s own planned trials, are expected to provide critical data that could enhance the company’s market position. These factors collectively suggest a strong growth potential for RAPT Therapeutics, justifying the Buy recommendation.
According to TipRanks, Slutsky is an analyst with an average return of -2.1% and a 37.57% success rate. Slutsky covers the Healthcare sector, focusing on stocks such as Abivax SA Sponsored ADR, Cogent Biosciences, and Celldex.
In another report released on July 10, H.C. Wainwright also maintained a Buy rating on the stock with a $27.00 price target.